| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EIF4H |
| Uniprot No | Q15056 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-248aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSHMADFDT YDDRAYSSFG GGRGSRGSAG GHGSRSQKEL PTEPPYTAYV GNLPFNTVQG DIDAIFKDLS IRSVRLVRDK DTDKFKGFCY VEFDEVDSLK EALTYDGALL GDRSLRVDIA EGRKQDKGGF GFRKGGPDDR GMGSSRESRG GWDSRDDFNS GFRDDFLGGR GGSRPGDRRT GPPMGSRFRD GPPLRGSNMD FREPTEEERA QRPRLQLKPR TVATPLNQVA NPNSAIFGGA RPREEVVQKE QE |
| 预测分子量 | 30 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Recombinant EIF4H Protein Enhances Translation Initiation in Vitro"**
*作者：Jing Zhang等*
摘要：研究通过大肠杆菌表达系统成功纯化重组EIF4H蛋白，证实其可显著提高体外翻译系统的效率，并解析了其与mRNA 5'端结合的分子机制。
2. **"EIF4H Overexpression Promotes Cancer Cell Proliferation via mTOR Signaling"**
*作者：Nathaniel Robichaud等*
摘要：利用重组EIF4H进行功能研究，发现其在肺癌细胞中过表达通过激活mTOR通路加速肿瘤生长，提示EIF4H作为潜在治疗靶点。
3. **"Structural Analysis of EIF4H in Complex with eIF4E Reveals mRNA Recruitment Dynamics"**
*作者：Maria M. Alepuz等*
摘要：通过X射线晶体学解析重组EIF4H与eIF4E的复合物结构，揭示其在mRNA招募中的动态相互作用，为翻译起始复合物组装提供结构基础。
4. **"EIF4H Knockdown Impairs Viral RNA Translation in Influenza-Infected Cells"**
*作者：Siddharth Balachandran等*
摘要：研究表明，利用siRNA沉默EIF4H或添加重组竞争性突变体蛋白，可抑制流感病毒RNA的翻译，证实其在宿主-病毒互作中的关键作用。
Eukaryotic Translation Initiation Factor 4H (EIF4H) is a regulatory protein involved in the initiation phase of mRNA translation, a critical step in protein synthesis. As a component of the eukaryotic translation initiation factor 4F (eIF4F) complex, EIF4H interacts with other initiation factors, such as EIF4A and EIF4G, to facilitate ribosome recruitment and scanning of mRNA. It enhances the helicase activity of EIF4A, promoting the unwinding of secondary structures in the 5' untranslated region (UTR) of mRNAs, thereby ensuring efficient translation under normal and stress conditions.
Recombinant EIF4H is produced through genetic engineering, typically by cloning the EIF4H gene into expression vectors (e.g., bacterial, insect, or mammalian systems) followed by purification via affinity chromatography. Its recombinant form retains functional properties, enabling studies on translational regulation mechanisms. Researchers utilize recombinant EIF4H to investigate its role in cellular processes, including cell proliferation, stress responses, and viral infection, where translational control is disrupted.
Dysregulation of EIF4H has been linked to diseases such as cancer, neurodegenerative disorders, and viral pathogenesis. Overexpression of EIF4H is observed in certain cancers, correlating with enhanced translation of oncoproteins and tumor progression. Consequently, it is explored as a potential therapeutic target. Recombinant EIF4H also aids in structural studies, drug screening, and understanding interactions with RNA or other translation factors. Its applications extend to developing assays for monitoring translational fidelity or identifying inhibitors of pathological translation pathways. Overall, recombinant EIF4H serves as a vital tool for dissecting the molecular basis of translation and its implications in health and disease.
×
